Locoregional Recurrence Free Survival | Progression Free Survival | Overall Survival | ||||
---|---|---|---|---|---|---|
Unadjusted HR | Adjusted HR | Unadjusted HR | Adjusted HR | Unadjusted HR | Adjusted HR | |
15–18 aged (ref: >18years) | 0.80 (0.63–1.01); 0.065 | 0.86 (0.67–1.10); 0.226 | 1.00 (0.86–1.17); 0.968 | 0.85 (0.72–1.01); 0.063 | 0.98 (0.78–1.24); 0.862 | 0.76 (0.60–0.98); 0.033 |
Gender male (ref: female) | 0.87 (0.72–1.06); 0.169 | 0.91 (0.74–1.11); 0.354 | 1.16 (1.01–1.32); 0.034 | 1.05 (0.91–1.22); 0.476 | 1.33 (1.08–1.63); 0.007 | 1.20 (0.96–1.49); 0.110 |
de novo metastatic disease (ref: no) | --- | --- | 2.59 (2.18–3.07); <0.001 | 2.20 (1.83–2.64); <0.001 | 3.75 (2.99–4.68); <0.001 | 2.90 (2.29–3.67); <0.001 |
Tumor size ≤ 10 cm or not documented (ref:>10 cm) | 1.14 (0.88–1.46); 0.292 | 0.94 (0.72–1.22); 0.632 | 2.59 (2.18–3.07); <0.001 | 0.79 (0.67–0.93); 0.006 | 0.66 (0.53–0.83); <0.001 | 0.82 (0.64–1.04); 0.102 |
Lower limb (ref: other) | 0.67 (0.540.82); <0.001 | 0.73 (0.59–0.92); 0.008 | 0.72 (0.63–0.83); <0.001 | 0.76 (0.66–0.89); <0.001 | 0.59 (0.48–0.74); <0.001 | 0.60 (0.47–0.76); <0.001 |
Site of tumor Bone (ref: Soft tissue) | 0.97 (0.79–1.17); 0.736 | 1.43 (1.13–1.81); 0.003 | 1.05 (0.92–1.20); 0.503 | 1.07 (0.91–1.25); 0.417 | 0.98 (0.80–1.20); 0.842 | 0.87 (0.69–1.11); 0.259 |
Tumor grade Grade 3 (ref: grades 1–2) | 1.04 (0.75–1.44); 0.823 | 1.02 (0.73–1.43); 0.910 | 2.69 (2.09–3.46); <0.001 | 2.20 (1.76–2.98); <0.001 | 3.85 (2.51–5.88); <0.001 | 3.27 (2.11–5.05); <0.001 |
Ungraded tumor (ref: grades 1–2) | 1.99 (1.44–2.77); <0.001 | 1.82 (1.31–2.53); <0.001 | 1.97 (1.49–2.59); <0.001 | 1.88 (1.42–2.49); <0.001 | 1.05 (0.63–1.76); 0.847 | 1.10 (0.65–1.86); 0.711 |
AYA in RSC (ref: AYA in non-RSC) | 0.58 (0.47;0.70); <0.001 | 0.58 (0.46–0.73); <0.001 | 0.86 (0.76–0.99); 0.035 | 0.83 (0.71–0.97); 0.021 | 1.12 (0.91–1.39); 0.269 | 1.10 (0.87–1.40); 0.392 |